https://scholars.lib.ntu.edu.tw/handle/123456789/431124
標題: | Trifluoperazine, an antipsychotic drug, effectively reduces drug resistance in cisplatin-resistant urothelial carcinoma cells via suppressing bcl-xl: An in vitro and in vivo study | 作者: | Kuo K.-L. SHING-HWA LIU WEI-CHOU LIN Hsu F.-S. PO-MING CHOW Chang Y.-W. Yang S.-P. Shi C.-S. Hsu C.-H. Liao S.-M. HONG-CHIANG CHANG KUO-HOW HUANG |
公開日期: | 2019 | 出版社: | MDPI AG | 卷: | 20 | 期: | 13 | 來源出版物: | International Journal of Molecular Sciences | 摘要: | Cisplatin-based chemotherapy is the primary treatment for metastatic bladder urothelial carcinoma (UC). Most patients inevitably encounter drug resistance and resultant disease relapse. Reduced apoptosis plays a critical role in chemoresistance. Trifluoperazine (TFP), an antipsychotic agent, has demonstrated antitumor effects on various cancers. This study investigated the efficacy of TFP in inhibiting cisplatin-resistant bladder UC and explored the underlying mechanism. Our results revealed that cisplatin-resistantUCcells (T24/R) upregulated the antiapoptotic factor, B-cell lymphoma-extra large (Bcl-xL). Knockdown of Bcl-xL by siRNA resensitized cisplatin-resistant cells to the cisplatin cytotoxic effect. TFP (10–45 μM) alone elicited dose-dependent cytotoxicity, apoptosis, and G0/G1 arrest on T24/R cells. Co-treatment of TFP potentiated cisplatin-induced cytotoxicity in T24/R cells. The phenomenon that TFP alleviated cisplatin resistance to T24/R was accompanied with concurrent suppression of Bcl-xL. In vivo models confirmed that TFP alone effectively suppressed the T24/R xenograft in nude mice. TFP co-treatment enhanced the antitumor effect of cisplatin on the T24/R xenograft. Our results demonstrated that TFP effectively inhibited cisplatin-resistant UCs and circumvented cisplatin resistance with concurrent Bcl-xL downregulation. These findings provide a promising insight to develop a therapeutic strategy for chemoresistant UCs. ? 2019 by the authors. Licensee MDPI, Basel, Switzerland. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85069263170&doi=10.3390%2fijms20133218&partnerID=40&md5=98d12fc6531022042fbd8abf874df3eb https://scholars.lib.ntu.edu.tw/handle/123456789/431124 |
ISSN: | 1661-6596 | DOI: | 10.3390/ijms20133218 | SDG/關鍵字: | caspase 4; cisplatin; cyclin dependent kinase inhibitor; fluorescein isothiocyanate; neuroleptic agent; protein bcl xl; protein p21; protein p27; trifluoperazine; antineoplastic agent; cisplatin; neuroleptic agent; protein bcl x; trifluoperazine; animal cell; animal experiment; animal model; antiapoptotic activity; antineoplastic activity; apoptosis; apoptosis assay; Article; cell culture; cell stress; cell viability; cell viability assay; chemotherapy; cisplatin resistant urothelial carcinoma cell; cisplatin-resistant cell line; cytotoxicity; DNA damage; down regulation; endoplasmic reticulum stress; flow cytometry; gene knockdown; genetic transfection; in vitro study; in vivo study; mouse; MTT assay; nonhuman; percentage of cells in G0/G1 phase; protein expression; T24 cell line; transitional cell carcinoma; tumor volume; upregulation; Western blotting; xenograft; animal; bladder tumor; carcinoma; cell line; drug effect; drug resistance; genetics; human; metabolism; pathology; urothelium; Animals; Antineoplastic Agents; Antipsychotic Agents; Apoptosis; bcl-X Protein; Carcinoma; Cell Line; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Humans; Mice; Trifluoperazine; Urinary Bladder Neoplasms; Urothelium |
顯示於: | 毒理學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。